Exploring Ex-US Markets To Reduce Risk For Your Clinical Trials

As U.S. regulatory pathways grow more complex, many sponsors are turning to international markets to safeguard progress and strengthen their clinical trial strategies. Novotech experts Renita Hite and Scott Schliebner share how biotech and emerging pharma companies are increasingly leveraging regions such as APAC and Eastern Europe to accelerate trial start-up, secure high-quality data, and optimize costs.

This is part three of the four-part series "Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials", offering a timely perspective on how global expansion can position sponsors for success in 2025 and beyond. This discussion highlights why expanding beyond U.S. borders has become a strategic advantage—offering speed, flexibility, and resilience at a time when domestic uncertainty can slow momentum. Listeners will gain insights into the benefits of global site integration along with practical considerations for building international networks. Our speakers also examine common challenges sponsors face in ex-U.S. markets and provide strategies to mitigate risk while maintaining compliance and data integrity.